MARKET

CRBU

CRBU

Caribou Biosciences, Inc.
NASDAQ
2.140
+0.020
+0.94%
Pre Market: 2.170 +0.03 +1.40% 06:48 05/15 EDT
OPEN
2.130
PREV CLOSE
2.120
HIGH
2.320
LOW
1.990
VOLUME
10.90K
TURNOVER
0
52 WEEK HIGH
3.535
52 WEEK LOW
0.7691
MARKET CAP
212.25M
P/E (TTM)
-1.5084
1D
5D
1M
3M
1Y
5Y
1D
Caribou Biosciences to join H.C. Wainwright BioConnect investor conference fireside chat
PUBT · 1d ago
Need To Know: Analysts Are Much More Bullish On Caribou Biosciences, Inc. (NASDAQ:CRBU) Revenues
Simply Wall St · 2d ago
Bank of America Securities Remains a Buy on Caribou Biosciences (CRBU)
TipRanks · 2d ago
FDA Commissioner Marty Makary resigns
TipRanks · 2d ago
Caribou Biosciences To Present Phase 1 CAR-T Therapy Data For vispa-cel And CB-011 At EHA 2026 Annual Meeting
Benzinga · 3d ago
Caribou Biosciences to present vispa-cel data at EHA annual meeting
PUBT · 3d ago
Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting
Barchart · 3d ago
Caribou Biosciences Price Target Raised to $11.00/Share From $9.00 by HC Wainwright & Co.
Dow Jones · 4d ago
More
About CRBU
Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company engaged in developing transformative therapies for patients with devastating diseases. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform to offer broad access and rapid availability of treatments for patients with hematologic malignancies and autoimmune diseases. Its genome-editing platform, including its novel chRDNA technology, enables more precise genome editing of allogeneic cell therapies. It is advancing its pipeline of allogeneic CAR-T cell therapies with clinical development programs targeting the treatment of hematologic malignancies and autoimmune diseases.

Webull offers Caribou Biosciences Inc stock information, including NASDAQ: CRBU real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRBU stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRBU stock methods without spending real money on the virtual paper trading platform.